Karyopharm Therapeutics (NASDAQ:KPTI) Stock Passes Below Two Hundred Day Moving Average of $1.09

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.09 and traded as low as $0.75. Karyopharm Therapeutics shares last traded at $0.76, with a volume of 481,267 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on KPTI shares. StockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $4.80.

Karyopharm Therapeutics Stock Down 1.4 %

The firm has a market capitalization of $94.73 million, a PE ratio of -0.60 and a beta of 0.21. The business's fifty day moving average price is $0.88 and its 200 day moving average price is $1.09.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to analysts' expectations of $36.07 million. On average, analysts anticipate that Karyopharm Therapeutics Inc. will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 468,044 shares of the business's stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $0.96, for a total value of $449,322.24. Following the transaction, the director now directly owns 3,385 shares of the company's stock, valued at approximately $3,249.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 1,074,687 shares of company stock valued at $1,043,723 over the last three months. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth $339,000. BNP Paribas Financial Markets boosted its holdings in Karyopharm Therapeutics by 6.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company's stock worth $1,530,000 after buying an additional 108,286 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in Karyopharm Therapeutics during the fourth quarter worth about $197,000. Monashee Investment Management LLC purchased a new position in Karyopharm Therapeutics in the fourth quarter valued at about $115,000. Finally, Simplicity Wealth LLC acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter valued at approximately $66,000. Institutional investors and hedge funds own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).